A Phase 2 interventional study of Zactima (vandetanib) and Docetaxel in Prostate Cancer, Metastatic and Hormone Refractory, sponsored by Sanofi. Completed at 11 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-07.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.
Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 50th largest by enrollment of the 185 interventional ones that give a count, is one of 21 that started in 2005, is one of 104 in phase 2, and was the 91st registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+ · Men only
Charles Drew University of Medicine and Science · Sites in United States
Ages 18+ · Men only
Instituto do Cancer do Estado de São Paulo · Sites in Brazil
Ages 18+ · Men only
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Sites in France, Germany, Italy and 2 more countries
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 131 · Phase 3 34 · Phase 4 1
First in 1998; this study’s year is marked. 21 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 39 across the 185 interventional studies. Of the 143 that completed or were terminated, 53 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 193 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
34 studies in Prostatic Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 34 studies in Prostatic Neoplasms by Sanofi, this one is the 12th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2005, is one of 14 in phase 2, and was the 12th registered.
Sanofi’s Prostatic Neoplasms studies by the year they started, since 2001.
6 of the studies testing docetaxel in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT03574571Phase 3Memorial Sloan Kettering Cancer CenterA Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | 2027-04-01 |
| NCT06480110Rigshospitalet, DenmarkEbastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | 2026-12-01 |
| NCT04633252National Cancer Institute (NCI)A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer | 2026-12-31 |
| NCT04015622British Columbia Cancer AgencyPROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA | 2027-01-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 193 studies testing docetaxel in Prostatic Neoplasms, from their registry updates:
Among Sanofi’s 34 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether treatment with Zactima (vandetanib) in combination with Docetaxel and Prednisolone is more effective than the standard Docetaxel and Prednisolone alone for prostate cancer, in patients with Hormone refractory prostate cancer who have not previously received chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prostate Specific Antigen (PSA) Response
Prostate Specific Antigen (PSA) response was defined as a reduction of at least 50% from baseline at any assessment, confirmed by a second assessment 2-4 weeks after the initial response
Time frame: PSA measurements were to be performed at screening, at baseline (>2 weeks after screening) and every 3 weeks during the study. Any response was to be confirmed 2-4 weeks after the initial assessment of a 50% fall in PSA from baseline
Number of Patients With an Objective Disease Progression Event
Number of patients with objective disease progression or death (by any cause in the absence of objective progression)
Time frame: RECIST tumour assessments carried out at screening and then as per site clinical practice until objective progression. The only additional mandatory tumour assessment visit is at the point of data cut-off (21 July 2007 or up to 7 days in advance of DCO)
First patient randomised 24 January 2006, last patient randomised 24 Nov 2006, data cut off data 21 July 2007
| Milestone | Vandetanib | Placebo |
|---|---|---|
| Started | 43 | 43 |
| Completed | 5 | 14 |
| Not completed | 38 | 29 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Adverse event | 12 | 5 |
| Withdrew: Condition under investigation worsened | 19 | 21 |
| Withdrew: Other | 3 | 1 |
Prostate Specific Antigen (PSA) response was defined as a reduction of at least 50% from baseline at any assessment, confirmed by a second assessment 2-4 weeks after the initial response
| Participants | Vandetanib | Placebo |
|---|---|---|
| Prostate Specific Antigen (PSA) Response | 17 | 29 |
Number of patients with objective disease progression or death (by any cause in the absence of objective progression)
| Participants | Vandetanib | Placebo |
|---|---|---|
| Number of Patients With an Objective Disease Progression Event | 28 | 26 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vandetanib | — | 23/43 (53.5%) | 38/43 (88.4%) |
| Placebo | — | 15/43 (34.9%) | 39/43 (90.7%) |
| Event | Vandetanib | Placebo |
|---|---|---|
| PNEUMONIAInfections and infestations | 3/43 | 1/43 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 2/43 | 1/43 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 2/43 | 1/43 |
| ANAEMIABlood and lymphatic system disorders | 0/43 | 1/43 |
| NEUTROPENIABlood and lymphatic system disorders | 1/43 | 0/43 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/43 | 1/43 |
| BLINDNESSEye disorders | 1/43 | 0/43 |
| CONSTIPATIONGastrointestinal disorders | 0/43 | 1/43 |
| DIARRHOEAGastrointestinal disorders | 0/43 | 1/43 |
| DUODENAL ULCER HAEMORRHAGEGastrointestinal disorders | 0/43 | 1/43 |
| Event | Vandetanib | Placebo |
|---|---|---|
| ALOPECIASkin and subcutaneous tissue disorders | 16/43 | 19/43 |
| NAUSEAGastrointestinal disorders | 7/43 | 16/43 |
| FATIGUEGeneral disorders | 16/43 | 14/43 |
| DIARRHOEAGastrointestinal disorders | 10/43 | 13/43 |
| CONSTIPATIONGastrointestinal disorders | 4/43 | 10/43 |
| DYSGEUSIANervous system disorders | 8/43 | 5/43 |
| INSOMNIAPsychiatric disorders | 8/43 | 7/43 |
| LACRIMATION INCREASEDEye disorders | 4/43 | 7/43 |
| VOMITINGGastrointestinal disorders | 1/43 | 7/43 |
| ASTHENIAGeneral disorders | 5/43 | 7/43 |
| Age, Continuous(years) | Vandetanib | Placebo | Total |
|---|---|---|---|
| Mean | 67 (47 to 81) | 67 (43 to 79) | 67 (43 to 81) |
| Sex: Female, Male(Participants) | Vandetanib | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 43 | 43 | 86 |
The record gives a start of Dec 2005, a primary completion of Jul 2007 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Docetaxel · Prednisolone